Characterisation and optimisation of diclofenac sodium orodispersible thin film formulation

Khadra, Ibrahim and Obeid, Mohammad A. and Dunn, Claire and Watts, Stewart and Halbert, Gavin and Ford, Steven and Mullen, Alexander (2019) Characterisation and optimisation of diclofenac sodium orodispersible thin film formulation. International Journal of Pharmaceutics, 561. pp. 43-46. ISSN 1873-3476 (https://doi.org/10.1016/j.ijpharm.2019.01.064)

[thumbnail of Khadra-etal-IJP2019-Characterisation-and-optimisation-of-diclofenac-sodium-orodispersible]
Preview
 Text. Filename: Khadra_etal_IJP2019_Characterisation_and_optimisation_of_diclofenac_sodium_orodispersible.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (590kB)| Preview

Abstract

Oral Thin Film (OTF) is a newly emerging drug delivery system which has many benefits for patients. Although there has been some formulation of OTF products, these have mainly been as confectionary or dental health products. The most significant benefit of this dosage format will only be realised once more pharmaceutical products become available. Within this paper, OTF strips containing Diclofenac Sodium were prepared using the solvent casting method and then characterised to ensure the method could conform to acceptable levels of uniformity, the mean (SD) diclofenac sodium content was 25.43 (1.39) mg, range 22.84–27.44 mg. Bioburden was tested against coliforms, yeasts and moulds and all results were confirmed to be <10 CFU/g, also similar dissolution profile when compared to a commercial product to ensure biowaiver. An acceptable level of uniformity of mass was produced. K-F titration was employed to reduce the water content of the strips and it was found to be acceptable, this represented a level of water which would not be viable for microbial growth. The technique employed here in the production of OTF resulted in high quality products and amenability to being up scaled. Furthermore, the characterisation method was also sufficient to assess the quality of the products and may be used for future analysis of OTF pharmaceuticals.

ORCID iDs

Khadra, Ibrahim ORCID logoORCID: https://orcid.org/0000-0002-9846-1520, Obeid, Mohammad A., Dunn, Claire ORCID logoORCID: https://orcid.org/0000-0003-0265-7922, Watts, Stewart, Halbert, Gavin, Ford, Steven and Mullen, Alexander ORCID logoORCID: https://orcid.org/0000-0001-7475-5543;
CORE (COnnecting REpositories)